Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease. | ScholarDeck

Paper

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease.

New research · Neurology

Movement disorders clinical practice · 4w

Cohort studyMovement disorders clinical practice· Aug 2026

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease.

Mario Hero, Nadja Grozdanić, Romana Brnić Andrić … Vladimira Vuletić

Read paper

Movement DisordersCohort studyTreatmentQ2IF 2.2

Continuous foslevodopa/foscarbidopa infusion associated with improved motor symptoms at 1 year

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease.

Mario Hero … Vladimira Vuletić

Movement disorders clinical practice · Aug 2026 · Q2 in Neurology

Background

Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) provides 24-h delivery of levodopa-carbidopa prodrugs for advanced Parkinson's disease.

Purpose

To characterize 1-year changes in motor, non-motor, autonomic, quality-of-life and sleep outcomes, and in concomitant therapy.

Methods

Retrospective single-center observational study of 32 patients initiated on LDp/CDp between April 2024 and January 2026.

n = 32 patients

Results

motor symptom severity dropped by about a third

More results

Twenty of 32 patients (62.5%) completed 1-year follow-up.

Quality of life improved (p = 0.040), driven by bodily discomfort.

Levodopa-equivalent dose rose by 31.7% while oral dopamine agonist use fell from 70% to 25% (p = 0.004).

“

Conclusion

One year of LDp/CDp was associated with substantial motor benefit and improved quality of life, achieved with higher levodopa equivalent and reduced dopamine agonist use.

Read paper

0 comments

No comments yet. Be the first.

ScholarDeck.

Join the discussion on this paper

Create your profile

Related papers

Latest Foundational

Review

“Future studies should explore combinations of interventions and include longer follow-up periods to assess the long-term effects of these treatments.”

Cohort Study

45 minutes

brain blood-flow monitoring found no abnormalities after visual symptoms

Case Report

“The importance of timely recognition of optic neuropathy as a complication of amiodarone and dronedarone treatment may enable discontinuing the drug, thus preventing permanent vision loss.”

Review

“The following review will examine retinal changes that are suggested as possible biomarkers for Alzheimer's disease and discuss directions for future research in the field.”

Case-control

91%

this diameter correctly identifies most patients with HIE

Case Report

9 years

time from uveitis diagnosis to multiple sclerosis diagnosis

Cohort Study

54.8%

more than half of neonates with encephalopathy lacked traditional acidemia criteria

Cohort Study

8 weeks

half took longer than 2 months to reach a surgical decision